Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease

Circulation Journal

Volumn 73, Issue 8, 2009, Pages 1523-1530

  Arao, Kenshiro ^a   Yasu, Takanori ^b   Umemoto, Tomio ^a   Jinbo, Sachimi ^a   Ikeda, Nahoko ^a   Ueda, Shinichiro ^b   Kawakami, Masanobu ^a   Momomura, Shin Ichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Angina pectoris; Endothelial function; Oxidative stress; Postprandial dyslipidemia; Rheology

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BLOOD RHEOLOGY; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EATING; ENDOTHELIAL DYSFUNCTION; FOREARM BLOOD FLOW; HUMAN; HYPEREMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; JAPANESE; MALE; NON INVASIVE PROCEDURE; OXIDATIVE STRESS; POSTPRANDIAL STATE; SINUS BRADYCARDIA; TEST MEAL; URINALYSIS;

ADIPONECTIN; AGED; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FASTING; HEMORHEOLOGY; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; POSTPRANDIAL PERIOD; QUINOLINES; REGIONAL BLOOD FLOW;

EID: 69049107753     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0917     Document Type: Article

References (55)

1. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary Strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008; 51: 249-255.
2. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-316. (Pubitemid 47080485)
3. Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308. (Pubitemid 47080484)
4. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924. (Pubitemid 29241045)
5. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004; 164: 2090-2095.
6. O'Keefe JH, Bell DS. The post-prandial hyperglycemia/hyperlipemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904. (Pubitemid 47268287)
7. O'Driscoll G, Green D, Tayor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131. (Pubitemid 27097821)
8. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirschhoff N, Schulz S, et al. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-2363. (Pubitemid 40647072)
9. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719. (Pubitemid 34219772)
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
11. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
13. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218. (Pubitemid 34988638)
14. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-2524.
15. Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol 2008; 125: 136-138. (Pubitemid 351305417)
16. Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb 2007; 36: 1-8.
17. Bae JH, Bassenge E, Lee HJ, Park KR, Park CG, Park KY, et al. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: Effects of ACE inhibitors and fibrates. Atherosclerosis 2001; 158: 165-171.
18. Umemoto T, Yasu T, Arao K, Ishida T, Ikeda N, Kubo N, et al. Effects of eicosapentaenoic acid (EPA) on hemorheological behavior and endothelial function during postprandial hyperlipidemia and hyperglycemia in patients with stable effort angina pectoris. Jichi Med School J 2005; 28: 51-62 (in Japanese).
19. + cells after myocardial infarction treated by bare metal stent implantation. Circ J 2008; 72: 897-901. (Pubitemid 351888257)
20. Kawano T, Saito T, Yasu T, Saito T, Nakamura T, Namai K, et al. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism 2005; 54: 653-656. (Pubitemid 40585655)
21. Kikuchi Y, Sato K, Ohki H, Kaneko T. Optically accessible microchannels formed in a single-crystal silicon substrate for studies of blood rheology. Microvasc Res 1992; 44: 226-240.
22. Fukuda S, Yasu T, Kobayashi N, Ikeda N, Schmid-Shönbein GW. Contribution of fluid shear response in leukocytes to hemodynamic resistance in the spontaneously hypertensive rat. Circ Res 2004; 95: 100-108. (Pubitemid 38931841)
23. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Kajiyama G, Oshima T. A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol 2001; 87: 121-125. (Pubitemid 32013961)
24. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
25. Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott RS. The postprandial state does not impair endothelial function in women with type 2 diabetes irrespective of glycaemic control. Diabetologia 2004; 47: 1838-1846. (Pubitemid 40022421)
26. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610. (Pubitemid 26187348)
27. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898. (Pubitemid 26293305)
28. Shinozaki K, Nishio Y, Okamura T, Toshida Y, Maegawa H, Kojima H, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rat. Circ Res 2000; 87: 566-573. (Pubitemid 30745351)
29. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998; 97: 2519-2526. (Pubitemid 28294498)
30. Wilmink HW, Twickler MB, Banga JD, Dallinga-Thie GM, Eeltink H, Erkelens DW, et al. Effect of statin versus fibrate on postprandial endothelial dysfunction: Role of remnant-like particles. Cardiovasc Res 2001; 50: 577-582. (Pubitemid 32480251)
31. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-2860. (Pubitemid 29258971)
32. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026. (Pubitemid 37377262)
33. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
34. Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007; 194: e43-e51. (Pubitemid 47513070)
35. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457. (Pubitemid 39281400)
36. Ando H, Sugimoto KI, Yanagihara H, Tsuruoka S, Saito T, Takamura T, et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008; 35: 1012-1017.
37. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007; 71: 144-152. (Pubitemid 46045564)
38. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762. (Pubitemid 41372115)
39. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: 1510-1517. (Pubitemid 47124181)
40. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Saito M, et al. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ J 2006; 70: 1557-1562. (Pubitemid 44819870)
41. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599-2606. (Pubitemid 44300977)
42. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, et al. Vascular lipotoxicity: Endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148: 160-165. (Pubitemid 46021448)
43. Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 2008; 102: 68-76.
44. Wassmann S, Hilgers S, Laufs U, Böhm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arteriosc Thromb Vasc Biol 2002; 22: 300-305. (Pubitemid 34127043)
45. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457. (Pubitemid 34225391)
46. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001; 88: 1291-1294. (Pubitemid 33132098)
47. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002; 22: 799-804.
48. Sugano R, Matsuoka H, Haramaki N, Umei H, Murase E, Fukami K, et al. Polymorphonuclear leukocytes may impair endothelial function: Results of crossover randomized study of lipid-lowering therapies. Arterioscler Thromb Vasc Biol 2005; 25: 1262-1267. (Pubitemid 40776619)
49. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82. (Pubitemid 27029946)
50. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-24271. (Pubitemid 28435775)
51. Wang J, Tokoro T, Matsui K, Higa S, Kitajima I. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci 2005; 76: 2257-2268. (Pubitemid 40283650)
52. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692. (Pubitemid 32588024)
53. Tsuda Y, Satoh K, Takahashi T, Kitadai M, Ichihara S, Ayada Y, et al. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia. Int Angiol 1993; 12: 360-364. (Pubitemid 24089239)
54. Haak E, Abletshauser C, Weber S, Goedicke C, Martin N, Germanns N, et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 2001; 155: 395-401. (Pubitemid 32209310)
55. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999; 95: 229-234. (Pubitemid 29428154)